SUBSTITUTED 2-PHENYL BENZOFURANS AS ESTROGENIC AGENTS

Details for Australian Patent Application No. 2002366356 (hide)

Owner WYETH

Inventors KAUFMAN, David, Harry; MORRIS, Robert, Lester; SINGHAUS, Robert, Ray, Jr.; ULLRICH, John, William; HARRIS, Heather, Anne; KEITH, James, Carl, Jr.; ALBERT, Leo, Massillamoney; UNWALLA, Rayomand, J.; MILLER, Christopher, Paul; COLLINI, Michael, David

Pub. Number AU-A-2002366356

PCT Number PCT/US02/40224

PCT Pub. Number WO2003/051860

Priority 60/341,638 18.12.01 US

Filing date 17 December 2002

Wipo publication date 30 June 2003

International Classifications

C07D 307/80 Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom

A61K 031/34 - having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide

A61P 005/00 Drugs for disorders of the endocrine system

Event Publications

28 August 2003 Application Open to Public Inspection

  Published as AU-A-2002366356

28 August 2003 Complete Application Filed

  Priority application(s): 60/341,638 18.12.01 US

16 September 2004 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(f)/See Reg. 8.3(3). Examination has not yet been requested or directed for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002366357-IDENTIFICATION OF ESSENTIAL GENES OF CRYPTOCOCCUS NEOFORMANS AND METHODS OF USE

2002366355-SEQUESTRATION OF ABeta IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES